News und Analysen
![Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and
![Puma Biotechnology Reports First Quarter 2020 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Puma Biotechnology Reports First Quarter 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020. Unless otherwise stated, all comparisons are for the
![Savara Reports First Quarter 2020 Financial Results and Provides Business Update](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Savara Reports First Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a business update.
“With the recent clarity
![Xencor Reports First Quarter 2020 Financial Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor Reports First Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
![NanoString Technologies Releases Operating Results for First Quarter of 2020](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
NanoString Technologies Releases Operating Results for First Quarter of 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter of 2020.
![Premier Inc. Survey: Hospitals’ COVID-19 Testing Capacity Must at Least Triple Before Elective Surgeries Can Fully Resume](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Premier Inc. Survey: Hospitals’ COVID-19 Testing Capacity Must at Least Triple Before Elective Surgeries Can Fully Resume
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new survey results finding that healthcare facilities need to expand their current COVID-19 testing capacity by
![Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in
![Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets
![Quidel Reports First Quarter 2020 Financial Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel Reports First Quarter 2020 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first
![STAAR Surgical Reports First Quarter 2020 Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
STAAR Surgical Reports First Quarter 2020 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
![Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will provide an overview of the Company at 3:40 p.m. EDT on Wednesday, May 13, at the BofA Securities Health Care Conference
![NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
![Transgene Reports Q1 2020 Financial Position and Business Update](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Transgene Reports Q1 2020 Financial Position and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
![Premier Inc. Puts Unmatched Insights at Clinicians’ Fingertips with Launch of Perinatal Quality Dashboard](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Premier Inc. Puts Unmatched Insights at Clinicians’ Fingertips with Launch of Perinatal Quality Dashboard
Premier Inc. (NASDAQ: PINC) is advancing care for mothers and infants with the launch of its Perinatal Quality Dashboard that delivers self-service, actionable insights to support clinicians on the
![Humana Jumps 17 Spots on Benchmark List of Top 50 Companies for Diversity](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Humana Jumps 17 Spots on Benchmark List of Top 50 Companies for Diversity
Humana Inc. (NYSE: HUM) rose dramatically on the DiversityInc list of Top 50 Companies for Diversity, jumping 17 spots in making the list for the third year in a row. The list honors leadership in
![Clovis Oncology Announces First Quarter 2020 Operating Results](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Clovis Oncology Announces First Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and
![Premier Inc. Reports Fiscal 2020 Third-Quarter Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Premier Inc. Reports Fiscal 2020 Third-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 third quarter ended March 31, 2020.
All results presented in this press release reflect continuing operations
![Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to
![Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to
![Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
![Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
![Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development
Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development
![Acadia Healthcare Reports First Quarter 2020 Results](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Acadia Healthcare Reports First Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2020, and provided an update on the impact of the COVID-19 pandemic.
![Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes
![Humana-Owned Health Care Facilities Implement New COVID-19 Prevention Standards](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Humana-Owned Health Care Facilities Implement New COVID-19 Prevention Standards
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that its senior-focused primary care subsidiaries Conviva Care Centers, Partners in Primary Care, and Family Physicians